SEARCH

SEARCH BY CITATION

References

  • 1
    Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci USA. 2002; 99: 821924.
  • 2
    Folkman J. Angiogenesis. Annu Rev Med. 2006; 57: 118.
  • 3
    Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999; 85: 2218.
  • 4
    Grant MB, May W, Caballero S, Brown G, Guthrie S, Mames R, Byrne B, Vaught T, Spoerri P, Peck A, Scott E. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med. 2002; 8: 60712.
  • 5
    Schatteman GC. Adult bone marrow-derived heman-gioblasts, endothelial cell progenitors, and EPCs. Curr Top Dev Biol. 2004; 64: 14180.
  • 6
    Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye. 2002; 16: 24260.
  • 7
    Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2004; 242: 91101.
  • 8
    Tong JP, Yao YF. Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. Clin Biochem. 2006; 39: 26776.
  • 9
    Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role of growth factors in the patho-genesis of diabetic retinopathy. Expert Opin Investig Drugs. 2004; 13: 127593.
  • 10
    Borgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 1999; 19: 420314.
  • 11
    Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 2005; 293: 150913.
  • 12
    Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003; 22: 129.
  • 13
    Choueiri TK, Bukowski RM, Rini BI. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. Semin Oncol. 2006; 33: 596606.
  • 14
    Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res. 2007; 13: 1098106.
  • 15
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355: 141931.
  • 16
    Chang KH, Chang-Ling T, McFarland E, Afzal A, Pan H, Baxter L, Shaw L, Caballero S, Sengupta N, Li Calzi S, Sullivan S, Grant MB. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci USA. 2007; 104: 10595600.
  • 17
    Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer. 2001; 8: 16173.
  • 18
    Blazquez C, Cook N, Micklem K, Harris AL, Gatter KC, Pezzella F. Phosphorylated KDR can be located in the nucleus of neoplastic cells. Cell Res. 2006; 16: 938.
  • 19
    Carpenter G. Nuclear localization and possible functions of receptor tyrosine kinases. Curr Opin Cell Biol. 2003; 15: 1438.
  • 20
    Fortini ME. Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat Rev Mol Cell Biol. 2002; 3: 67384.
  • 21
    Heldin CH, Ericsson J. Signal transduction. RIPping tyrosine kinase receptors apart. Science. 2001; 294: 21113.
  • 22
    Landman N, Kim TW. Got RIP? Presenilin-dependent intramembrane proteolysis in growth factor receptor signaling. Cytokine Growth Factor Rev. 2004; 15: 33751.
  • 23
    Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature. 1998; 393: 3826.
  • 24
    Weihofen A, Binns K, Lemberg MK, Ashman K, Martoglio B. Identification of signal peptide pepti-dase, a presenilin-type aspartic protease. Science. 2002; 296: 22158.
  • 25
    Xia W, Wolfe MS. Intramembrane proteolysis by pre-senilin and presenilin-like proteases. J Cell Sci. 2003; 116: 283944.
  • 26
    Rawson RB. Regulated intramembrane proteolysis: from the endoplasmic reticulum to the nucleus. Essays Biochem. 2002; 38: 15568.
  • 27
    Freeman M. Rhomboids. Curr Biol. 2003; 13: R586.
  • 28
    Moninka, N, Afzal A, Cai J, Chang K, Shaw L, Grant M, Boulton M. Cleavage and intracellular translocation of the-stromal derived factor -1 (sdf-1) receptor, CXCR4, regulates endothelial cell function. Invest Ophthalmol Vis Sci. 2008; 48: ARVO E-Abstract 1724.
  • 29
    Brunkan AL, Goate AM. Presenilin function and gamma-secretase activity. J Neurochem. 2005; 93: 76992.
  • 30
    Wolfe MS. The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry. 2006; 45: 79319.
  • 31
    Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem. 2006; 281: 360413.
  • 32
    De Strooper B. Nicastrin: gatekeeper of the gamma-secretase complex. Cell. 2005; 122: 31820.
  • 33
    Shah S, Lee S, Tabuchi K, Hao Y, Yu C, LaPlant Q, Ball H, Dann C, Sudhof T, Yu G. Nicastrin functions as a gamma-secretase-substrate receptor. Cell. 2005; 122: 43547.
  • 34
    Mastrangelo P, Matthews P, Chishti M, Schmidt S, Guy Y, Yang J, Mazella M, Coomaraswamy J, Horne P, Strome B, Pelly H, Levesque G, Ebeling C, Jiang Y, Nixon R, Rozmahel R, Fraser P, George-Hyslop P, Carlson G, Westaway D. Dissociated phenotypes in presenilin transgenic mice define functionally distinct gamma-secretases. Proc Natl Acad Sci USA. 2005; 102: 89727.
  • 35
    Kim SK, Park HJ, Hong HS, Baik EJ, Jung MW, Mook-Jung I. ERK1/2 is an endogenous negative regulator of the gamma-secretase activity. FASEB J. 2006; 20: 1579.
  • 36
    Pastorcic M, Das HK. Alternative initiation of transcription of the human presenilin 1 gene in SH-SY5Y and SK-N-SH cells. The role of Ets factors in the regulation of presenilin 1. Eur J Biochem. 2004; 271: 448594.
  • 37
    Wang R, Zhang Y, Sun P, Liu R, Zhang X, Xia K, Xia J, Xu H, Zhang Z. Transcriptional regulation of PEN-2, a key component of the gamma-secretase complex, by CREB. Mol Cell Biol. 2006; 26: 134754.
  • 38
    Massey LK, Mah AL, Monteiro MJ. Ubiquilin regulates presenilin endoproteolysis and modulates gamma-secretase components, Pen-2 and nicastrin. Biochem J. 2005; 391: 51325.
  • 39
    Allinson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res. 2003; 74: 34252.
  • 40
    Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell. 2000; 100: 3918.
  • 41
    Koike H, Tomioka S, Sorimachi H, Saido T, Maruyama K, Okuyama A, Fujisawa-Sehara A, Ohno S, Suzuki K, Ishiura S. Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. Biochem J. 1999; 343: 3715.
  • 42
    Ni CY, Murphy MP, Golde TE, Carpenter G. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001; 294: 217981.
  • 43
    Selkoe D, Kopan R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci. 2003; 26: 56597.
  • 44
    Kanning KC, Hudson M, Amieux PS, Wiley JC, Bothwell M, Schecterson LC. Proteolytic processing of the p75 neurotrophin receptor and two homologs generates C-terminal fragments with signaling capability. J Neurosci. 2003; 23: 542536.
  • 45
    Marambaud P, Shoi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, Baki L, Wen P, Efthimiopoulos S, Shao Z, Wisniewski T, Robakis N. A presenilin-1/gamma-secretase cleavage releases the E-cad-herin intracellular domain and regulates disassembly of adherens junctions. EMBO J. 2002; 21: 194856.
  • 46
    Parks AL, Curtis D. Presenilin diversifies its portfolio. Trends Genet. 2007; 23: 14050.
  • 47
    Murakami D, Okamoto I, Nagano O, Kawano Y, Tomita T, Iwatsubo T, De Strooper B, Yumoto E, Saya H. Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. Oncogene. 2003; 22: 15116.
  • 48
    Jung KM, Tan S, Landman N, Petrova K, Murray S, Lewis R, Kim PK, Kim DS, Ryu SH, Chao MV, Kim Tw. Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. J Biol Chem. 2003; 278: 421619.
  • 49
    May P, Reddy YK, Herz J. Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J Biol Chem. 2002; 277: 1873643.
  • 50
    McElroy B, Powell JC, McCarthy JV. The insulin-like growth factor 1 (IGF-1) receptor is a substrate for gamma-secretase-mediated intramembrane proteolysis. Biochem Biophys Res Commun. 2007; 358: 113641.
  • 51
    Marron M, Singh H, Tahir T, Kavumkal J, Kim H, Koh G, Brindle NP. Regulated proteolytic processing of Tie1 modulates ligand responsiveness of receptor -tyrosine kinase Tie 2. J Biol Chem. 2007; 282: 3050917.
  • 52
    Mukherjee S, Tessema M, Wandinger-Ness A. Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function. Circ Res. 2006; 98: 74356.
  • 53
    Myers JM, Martins GG, Ostrowski J, Stachowiak MK. Nuclear trafficking of FGFR1: a role for the transmembrane domain. J Cell Biochem. 2003; 88: 127391.
  • 54
    Peng H, Moffett J, Myers J, Fang X, Stachowiak E, Maher P, Kratz E, Hines J, Fluharty S, Mizukoshi E, Bloom D, Stachowiak M. Novel nuclear signaling pathway mediates activation of fibroblast growth factor-2 gene by type 1 and type 2 angiotensin II receptors. Mol Biol Cell. 2001; 12: 44962.
  • 55
    Reilly JF, Maher PA. Importin beta-mediated nuclear import of fibroblast growth factor receptor: role in cell proliferation. J Cell Biol. 2001; 152: 130712.
  • 56
    Bild AH, Turkson J, Jove R. Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J. 2002; 21: 325563.
  • 57
    Suga K, Saito A, Tomiyama T, Mori H, Akagawa K. Syntaxin 5 interacts specifically with presenilin holo-proteins and affects processing of betaAPP in neuronal cells. J Neurochem. 2005; 94: 42539.
  • 58
    McCarthy JV. Involvement of presenilins in cell-survival signalling pathways. Biochem Soc Trans. 2005; 33: 56872.
  • 59
    Thomas AV, Herl L, Spoelgen R, Hiltunen M, Jones PB, Tanzi RE, Hyman BT, Berezovska O. Interaction between presenilin 1 and ubiquilin 1 as detected by fluorescence lifetime imaging microscopy and a high-throughput fluorescent plate reader. J Biol Chem. 2006; 281: 264007.
  • 60
    Jo DG, Jang J, Kim BJ, Lundkvist J, Jung YK. Overexpression of calsenilin enhances gamma-secre-tase activity. Neurosci Lett. 2005; 378: 5964.
  • 61
    Prat MI, Adamo A, Gonzalez S, Affranchino J, Ikeda M, Matsubara E, Shoji M, Smith M, Castano E, Morelli L. Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration. Neurosci Lett. 2002; 326: 912.
  • 62
    Georgakopoulos A, Litterst C, Ghersi E, Baki L, Xu C, Serban G, Robakis NK. Metalloproteinase/-Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling. EMBO J. 2006; 25: 124252.
  • 63
    Arasada RR, Carpenter G. Secretase-dependent tyrosine phosphorylation of Mdm2 by the ErbB-4 intracellular domain fragment. J Biol Chem. 2005; 280: 307837.
  • 64
    Maatta JA, Sundvall M, Junttila TT, Peri L, Laine VJ, Isola J, Egeblad M, Elenius K. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell. 2006; 17: 6779.
  • 65
    Baki L, Shioi J, Wen P, Shao Z, Schwarzman A, Gama-Sosa M, Neve R, Robakis NK. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 2004; 23: 258696.
  • 66
    Kang DE, Yoon IS, Repetto E, Busse T, Yermian N, Ie L, Koo EH. Presenilins mediate phosphatidylinosi-tol 3-kinase/AKT and ERK activation via select signaling receptors. Selectivity of PS2 in platelet-derived growth factor signaling. J Biol Chem. 2005; 280: 3153747.
  • 67
    Lukiw WJ, Gordon WC, Rogaev EI, Thompson H, Bazan NG. Presenilin-2 (PS2) expression up-regulation in a model of retinopathy of prematurity and pathoangiogenesis. Neuroreport. 2001; 12: 537.
  • 68
    Nakajima M, Yuasa S, Ueno M, Takakura N, Koseki H, Shirasawa T. Abnormal blood vessel development in mice lacking presenilin-1. Mech Dev. 2003; 120: 65767.
  • 69
    Sainson RC, Aoto J, Nakatsu MN, Holderfield M, Conn E, Koller E, Hughes CC. Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. FASEB J. 2005; 19: 10279.
  • 70
    Serneels L, Dejaegere T, Craessaerts K, Horre K, Jorissen E, Tousseyn T, Hebert S, Coolen M, Martens G, Zwijsen A, Annaert W, Hartmann D, De Strooper B. Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. Proc Natl Acad Sci USA. 2005; 102: 171924.
  • 71
    Shi W, Harris AL. Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia. 2006; 11: 4152.
  • 72
    Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood. 2006; 107: 9319.
  • 73
    Nakajima M, Ogawa M, Shimoda Y, Hiraoka S, Iida M, Koseki H, Shirasawa T, Furukawa K. Presenilin-1 controls the growth and differentiation of endothelial progenitor cells through its beta-catenin-binding region. Cell Biol Int. 2006; 30: 23943.
  • 74
    Murakami Y, Yamagoe S, Noguchi K, Takebe Y, Takahashi N, Uehara Y, Fukazawa H. Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's sarcoma-associated herpes virus through Interaction with Daxx. J Biol Chem. 2006; 281: 2811321.
  • 75
    Mayo LD, Kessler KM, Pincheira R, Warren RS, Donner DB. Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase. J Biol Chem. 2001; 276: 251849.
  • 76
    Curry CL, Reed LL, Nickoloff BJ, Miele L, Foreman KE. Notch-independent regulation of Hes-1 expression by c-Jun N-terminal kinase signaling in human endothelial cells. Lab Invest. 2006; 86: 84252.
  • 77
    Taylor KL, Henderson AM, Hughes CC. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Microvasc Res. 2002; 64: 37283.
  • 78
    Takeshita K, Satoh M, Li M, Silver M, Limbourg F, Mukai Y, Rikitake Y, Radtke F, Gridley T, Losordo D, Liao J. Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res. 2007; 100: 708.
  • 79
    Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC, Herlyn M. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol. 2003; 23: 1425.
  • 80
    Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006; 66: 277884.
  • 81
    Hellstrom M, Phng L, Hofmann J, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson A, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe M, Kalem M, Gerhardt H, Betsholtz C. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007; 445: 77680.
  • 82
    Hainaud P, Contreres JO, Villemain A, Liu LX, Plouet J, Tobelem G, Dupuy E. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res. 2006; 66: 850110.
  • 83
    Harrington LS, Sainson RC, Williams CK, Taylor JM, Shi W, Li JL, Harris AL. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res. 2008; 75: 14454.
  • 84
    Thurston G, Noguera-Troise I, Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer. 2007; 7: 32731.
  • 85
    Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA. 1998; 95: 934954.
  • 86
    Nozaki M, Sakurai E, Raisler B, Baffi J, Witta J, Ogura Y, Brekken R, Sage E, Ambati B, Ambati J. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest. 2006; 116: 4229.
  • 87
    Yen L, Benlimame N, Nie Z, Xiao D, Wang T, Al Moustafa E, Esumi H, Milanini J, Hynes N, Pages G, Alaoui-Jamali. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell. 2002; 13: 402944.
  • 88
    Omerovic J, Puggioni EM, Napoletano S, Visco V, Fraioli R, Frati L, Gulino A, Alimandi M. Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res. 2004; 294: 46979.
  • 89
    Ni CY, Yuan H, Carpenter G. Role of the ErbB-4 car-boxyl terminus in gamma-secretase cleavage. J Biol Chem. 2003; 278: 45615.
  • 90
    Zhang YW, Wang R, Liu Q, Zhang H, Liao FF, Xu H. Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA. 2007; 104: 106138.
  • 91
    Amin DN, Hida K, Bielenberg DR, Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res. 2006; 66: 217380.
  • 92
    Bueter W, Dammann O, Zscheppang K, Korenbaum E, Dammann CE. ErbB receptors in fetal endothelium–a potential linkage point for inflammation-associated neonatal disorders. Cytokine. 2006; 36: 26775.
  • 93
    Kim HS, Shin HS, Kwak HJ, Cho CH, Lee CO, Koh GY. Betacellulin induces angiogenesis through activation of mitogen-activated protein kinase and phosphatidylinositol 3′-kinase in endothelial cell. FASEB J. 2003; 17: 31820.
  • 94
    Nakano N, Higashiyama S, Ohmoto H, Ishiguro H, Taniguchi N, Wada Y. The N-terminal region of NTAK/neuregulin-2 isoforms has an inhibitory activity on angiogenesis. J Biol Chem. 2004; 279: 1146570.
  • 95
    Russell KS, Stern DF, Polverini PJ, Bender JR. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol. 1999; 277: H220511.
  • 96
    Xiong S, Grijalva R, Zhang L, Nguyen NT, Pisters PW, Pollock RE, Yu D. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Res. 2001; 61: 172732.
  • 97
    Gulino D, Delachanal E, Concord E, Genoux Y, Morand B, Valiron M, Sulpice E, Scaife R, Alemany M, Vernet T. Alteration of endothelial cell monolayer integrity triggers resynthesis of vascular endothelium cadherin. J Biol Chem. 1998; 273: 2978693.
  • 98
    Navarro P, Caveda L, Breviario F, Mandoteanu I, Lampugnani MG, Dejana E. Catenin-dependent and -independent functions of vascular endothelial cadherin. J Biol Chem. 1995; 270: 3096572.
  • 99
    Prandini MH, Dreher I, Bouillot S, Benkerri S, Moll T, Huber P. The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis. Oncogene. 2005; 24: 29923001.
  • 100
    Parisiadou L, Fassa A, Fotinopoulou A, Bethani I, Efthimiopoulos S. Presenilin 1 and cadherins: stabilization of cell-cell adhesion and proteolysis-dependent regulation of transcription. Neurodegener Dis. 2004; 1: 18491.
  • 101
    Georgakopoulos A, Marambaud P, Friedrich VL Jr, Shioi J, Efthimiopoulos S, Robakis NK. Presenilin-1: a component of synaptic and endothelial adherens junctions. Ann N Y Acad Sci. 2000; 920: 20914.
  • 102
    Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001; 20: 70532.
  • 103
    Yoshida T, Ohno-Matsui K, Ichinose S, Sato T, Iwata N, Saido TC, Hisatomi T, Mochizuki M, Morita I. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest. 2005; 115: 2793800.
  • 104
    Zhang Y, Cai J, Afzal A, Grant M, Boulton M. VEGFR-1 is differentially regulated by pigment epithelium-derived factor (PEDF) via presenilin in RPE and retinal endothelial cells. Invest Ophthalmol Vis Sci. 2006; 47: ARVO E-Abstract 5333.
  • 105
    Yoneda S, Hara H, Hirata A, Fukushima M, Inomata Y, Tanihara H. Vitreous fluid levels of beta-amyloid((1–42)) and tau in patients with retinal diseases. Jpn J Ophthalmol. 2005; 49: 1068.
  • 106
    Hara H, Oh-hashi K, Yoneda S, Shimazawa M, Inatani M, Tanihara H, Kiuchi K. Elevated neprilysin activity in vitreous of patients with proliferative diabetic retinopathy. Mol Vis. 2006; 12: 97782.
  • 107
    Lazarov O, Robinson J, Tang Y, Hairston I, Korade-Mimics Z, Lee V, Hersh L, Sapolsky R, Mimics K, Sisodia S. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell. 2005; 120: 70113.
  • 108
    Cowan JW, Wang X, Guan R, He K, Jiang J, Baumann G, Black RA, Wolfe MS, Frank SJ. Growth hormone receptor is a target for presenilin-dependent gamma-secretase cleavage. J Biol Chem. 2005; 280: 1933142.
  • 109
    Schulz JG, Annaert W, Vandekerckhove J, Zimmermann P, De Strooper B, David G. Syndecan 3 intramembrane proteolysis is presenilin/gamma-secretase-dependent and modulates cytosolic signaling. J Biol Chem. 2003; 278: 486517.
  • 110
    Wang R, Tang P, Wang P, Boissy RE, Zheng H. Regulation of tyrosinase trafficking and processing by presenilins: partial loss of function by familial Alzheimer's disease mutation. Proc Natl Acad Sci USA. 2006; 103: 3538.
  • 111
    Cui W, Ke JZ, Zhang Q, Ke HZ, Chalouni C, Vignery A. The intracellular domain of CD44 promotes the fusion of macrophages. Blood. 2006; 107: 796805.
  • 112
    Carey BW, Kim DY, Kovacs DM. Presenilin/gamma-secretase and alpha-secretase-like peptidases cleave human MHC Class I proteins. Biochem J. 2007; 401: 1217.
  • 113
    Evin G, Sernee MF, Masters CL. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs. 2006; 20: 35172.
  • 114
    Milano J, Mckay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs R, Zacco A, Greenberg B, Ciaccio P. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004; 82: 34158.
  • 115
    Ni Y, Xhao X, Bao G, Zou L, Teng L, Wang Z, Song M, Xiong J, Bai Y, Pei G. Activation of beta2-adrener-gic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat Med. 2006; 12: 13906.
  • 116
    Czech C, Burns MP, Vardanian L, Augustin A, Jacobsen H, Baumann K, Rebeck GW. Cholesterol independent effect of LXR agonist TO-901317 on gamma-secretase. J Neurochem. 2007; 101: 92936.